Immunogenicity Clinical Trial
Official title:
Protectivity and Safety Following Recombinant Hepatitis B Vaccine With Different Source of Hepatitis B Bulk Compared to Hepatitis B (Bio Farma) Vaccine in Indonesian Population
Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population
Protectivity and Safety Following Recombinant Hepatitis B Vaccine with different source of Hepatitis B bulk compared to Hepatitis B (Bio Farma) vaccine in Indonesian Population. Experimental, randomized, double blind, four arm parallel group study, lot to lot consistency study. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05383560 -
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
|
Phase 2 | |
| Recruiting |
NCT01763268 -
Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05054621 -
Immunogenicity of COVID-19 Vaccine on Heterologous Schedule
|
Phase 2 | |
| Recruiting |
NCT05580159 -
New Generation mRNA Booster Vaccine Against Emerging VOCs
|
Phase 3 | |
| Active, not recruiting |
NCT05686161 -
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
|
Phase 3 | |
| Completed |
NCT04071379 -
Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B
|
Phase 3 | |
| Completed |
NCT01697007 -
A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique
|
Phase 2 | |
| Completed |
NCT03680417 -
Reactogenicity and Protectivity Following Measles- Rubella (MR) Routine Immunization in Indonesian Infants and Children
|
Phase 4 | |
| Completed |
NCT03722615 -
Epidemiology of Congenital Cytomegalovirus in a High HIV Prevalence Setting, South Africa
|
||
| Completed |
NCT01369927 -
Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
|
Phase 1 | |
| Completed |
NCT04051268 -
Immunogenicity and Safety of Vi-DT (Diphtheria Toxoid) Typhoid Conjugate Vaccine (Phase III)
|
Phase 3 | |
| Recruiting |
NCT05115617 -
Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study
|
||
| Not yet recruiting |
NCT05911087 -
A Phase II/III Study to Evaluate the Immunogenicity and Safety and Efficacy of SWIM816 Vaccines for SARS-CoV-2
|
Phase 2/Phase 3 | |
| Completed |
NCT01092195 -
Gardasil Vaccination in Post Stem Cell Transplant Patients
|
Phase 1 | |
| Completed |
NCT01399853 -
A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants
|
Phase 2 | |
| Completed |
NCT03460405 -
Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants
|
Phase 2 | |
| Completed |
NCT03681860 -
EMaBS TB Vaccine Study
|
Phase 1/Phase 2 | |
| Completed |
NCT04754698 -
COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS
|
Phase 4 | |
| Completed |
NCT04015232 -
Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
|
Phase 1 | |
| Recruiting |
NCT05150834 -
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
|